Everything below concerns peptide analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Fyodor Dostoevsky's book The Idiot had a character, General Ivolgin, who witnessed and recounted his relationship with Napoleon during the Campaign of Russia. Roger Brook is a fictional secret agent and Napoleonic Wars Era gallant, later identified as the Chevalier de Breuc, in a series of twelve novels by Dennis Wheatley. The Hornblower books by C.S. Forester follow the naval career of Horatio Hornblower during the Napoleonic Wars. The 1951 film "Captain Horatio Hornblower" starring Gregory Peck and Virginia Mayo and directed by Raoul Walsh is a film adaption based on Forester's series of novels. Also by C.S. Forester two novels of the Peninsular War in Spain and Portugal: "Death to the French" (1932, published in the United States under the title "Rifleman Dodd"), and "The Gun" (1933), later made into a 1957 film, "The Pride and the Passion", with Cary Grant, Frank Sinatra, Sophia Loren, directed by Stanley Kramer. R. F. Delderfield, two novels about the Napoleonic Wars; Seven Men of Gascony (1949) about seven French infantrymen serving in a succession of Napoleonic campaigns, and Too Few For Drums (1964) about British soldiers cut off behind the French lines in Portugal in 1810, during the Peninsular War. The Aubrey–Maturin series of novels is a sequence of 20 historical novels by Patrick O'Brian portraying the rise of Jack Aubrey from Lieutenant to Rear Admiral during the Napoleonic Wars. The film Master and Commander: The Far Side of the World starring Russell Crowe and directed by Peter Weir is based on this series of books.
Cardiomyoplasty is a surgical procedure in which healthy muscle from another part of the body is wrapped around the heart to provide support for the failing heart. Most often the latissimus dorsi muscle is used for this purpose. A special pacemaker is implanted to make the skeletal muscle contract. If cardiomyoplasty is successful and increased cardiac output is achieved, it usually acts as a bridging therapy, giving time for damaged myocardium to be treated in other ways, such as remodeling by cellular therapies.
== Effect on investment, sales and profit == According to Thomson Reuters in their 2012 publication "The Economic Power of Orphan Drugs", there has been increased investment in orphan drug research and development, partly due to the U.S. Orphan Drug Act of 1983 (ODA) and similar acts in other regions of the world driven by "high-profile philanthropic funding". According to a 2012 article in Drug Discovery Today, the years 2001 to 2011 were the "most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals". For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an "impressive 25.8%, compared to only 20.1% for a matched control group of non-orphan drugs". By 2012, the market for orphan drugs was worth US$637 million, compared with US$638 million for a control group of non-orphan drugs. By 2012,
==== Kinases ==== Protein kinases are the enzymes responsible for phosphorylation of serine and threonine residues. O-GlcNAc has been identified on over 100 (~20% of the human kinome) kinases, and this modification is often associated with alterations in kinase activity or kinase substrate scope. O-GlcNAc may have diverse functional consequences on kinases such as interfering with ATP binding, altering substrate recognition, or regulating other PTMs on kinases. Complex cross-talk relations can also exist where OGT and a kinase, e.g., AMPK, modify each other.
The loss of species from ecological communities, defaunation, is primarily driven by human activity. This has resulted in empty forests, ecological communities depleted of large vertebrates. In the Quaternary extinction event, the mass die-off of megafaunal variety coincided with the appearance of humans, suggesting a human influence. One hypothesis is that humans hunted large mammals, such as the woolly mammoth, into extinction. The 2019 Global Assessment Report on Biodiversity and Ecosystem Services by IPBES states that the total biomass of wild mammals has declined by 82 percent since the beginning of human civilization. Wild animals make up just 4% of mammalian biomass on earth, while humans and their domesticated animals make up 96%. Various species are predicted to become extinct in the near future, among them the rhinoceros, giraffes, and species of primates and pangolins. According to the WWF's 2020 Living Planet Report, vertebrate wildlife populations have declined by 68% since 1970 as a result of human activities, particularly overconsumption, population growth and intensive farming, which is evidence that humans have triggered a sixth mass extinction event. Hunting alone threatens hundreds of mammalian species around the world. Scientists claim that the growing demand for meat is contributing to biodiversity loss as this is a significant driver of deforestation and habitat destruction; species-rich habitats, such as significant portions of the Amazon rainforest, are being converted to agricultural land for meat production.
Sources: en.wikipedia.org
Fredric Sheldon Brandt (June 26, 1949 – April 5, 2015) was an American physician, researcher, lecturer, author, and radio host specializing in cosmetic dermatology. Among the first to use botulinum toxin ("botox") and fillers, Brandt was noted for his role in the FDA approval of numerous fillers and botulinum toxins for cosmetic use in the United States. Brandt, who hosted a radio show called Ask Dr. Brandt on SiriusXM radio and whose celebrity patients included Madonna, was called the "Baron of Botox" by W magazine and "King of Collagen" for using more botox and collagen than any other dermatologist in the world.
== History == The group began as a jangly indie pop band influenced by Primal Scream's early sound. By the time they recorded their first EP, Barging Into the Presence of God, released in 1989, the band went into a direction that displayed a mix of Ian Masters' ethereal, choirboy-like vocals along with dark atmospheric and noisy pop tunes. Ashley Horner from Edsel Auctioneer briefly joined the band on guitar in the same year. The band was signed to 4AD Records after their first London show by the label's chief Ivo Watts-Russell. The group's first album, The Comforts of Madness, was released in 1990 and reached the top 40 of the UK Albums Chart. The album's tracks were produced by John Fryer and Gil Norton. The album includes a cover version of "Fell from the Sun" by Opal. In late 1990, Meriel Barham, the original vocalist of Lush, joined the band as second guitarist and vocalist. Barham contributed backing vocals and guitars to the Chris Allison produced Half-Life EP, then joined permanently for the Nancy Sinatra cover "Kinky Love", which gave the band a minor hit single as part of Flesh Balloon EP. In 1992 the band recorded their second full-length album, In Ribbons, which was produced by Hugh Jones. Ian Masters left the band in 1993, citing his lack of enthusiasm for touring, unlike the remaining members of the band and their record label 4AD. Former Heart Throbs bassist Colleen Browne joined afterwards. Sticking with producer Hugh Jones, the group released the Fine Friend EP in mid-1994, followed by their third album, Slow Buildings.
== Reception == The review-aggregator website Rotten Tomatoes reported a 100% approval rating based on 36 critic reviews. According to the website's critics' consensus: "Tackling emotionally mature themes with an ingeniously zany sense of humor, Raphael Bob-Waksberg's Long Story Short welcomes viewers into a highly specific—and extremely relatable—family unit". Metacritic, which uses a weighted average, gave a score of 89 out of 100 based on 17 critics, indicating "universal acclaim". Jenna Scherer of The A.V. Club gave the show's first season a rating of A− and wrote: "The series is all about how people change over the years—and the fact that, no matter how far you run, the past always returns to haunt the present". Reviewing the series' first season for The Guardian, Stuart Heritage gave a rating of 4/5, saying it "reminds us that everything is an echo of what came before. This is a testament to Bob-Waksberg's writing. This level of granular, non-linear character development must have been a feat to construct, and yet it feels effortless."
Greenland's prime minister Jens-Frederik Nielsen thanked the European allies for their support. Ursula von der Leyen said in a speech at the World Economic Forum on 20 January that geopolitical "shocks" and Trump's worldview require a "new form of European independence." She underlined that the sovereignty and integrity of the Kingdom of Denmark including Greenland is non-negotiable. Hungarian Foreign Minister Péter Szijjártó stated that the EU does not need to deal with the Greenland crisis because it is only a dispute between Denmark and the US. There have been claims that Hungary and Prime Minister Viktor Orbán have provided behind the scenes support for Donald Trump's territorial claims concerning Greenland. At the same time, Szijjártó's statement violates several obligations and expectations associated with EU membership, given that Denmark is also a member of the EU. At the height of the crisis, there also emerged calls and petitions to boycott the 2026 FIFA World Cup, planned for the next summer and co-hosted by the United States. On 6 February, France and Canada announced the opening of their respective consulates in Nuuk in support of Greenlanders.
Azinphos-methyl (Guthion) (also spelled azinophos-methyl) is a broad spectrum organophosphate insecticide manufactured by Bayer CropScience, Gowan Co., and Makhteshim Agan. Like other pesticides in this class, it owes its insecticidal properties (and human toxicity) to the fact that it is an acetylcholinesterase inhibitor (the same mechanism is responsible for the toxic effects of the V-series nerve agent chemical weapons). It is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.
Sources: en.wikipedia.org
== Economy == Fishing is the primary occupation. The islands have strategic and economic value, in terms of fisheries and also mineral deposits of pyrite, sulfur, and various polymetallic ores. There are hopes that oil exploration will provide an economic boost to the islands. In 2014, construction workers built a pier and a breakwater in Kitovy Bay, central Iturup, where barges are a major means of transport, sailing between the cove and ships anchored offshore. A new road has been carved through the woods near Kurilsk, the island's biggest village, going to the site of Iturup Airport (on Kunashir, the neighboring island south of Iturup, there exists Yuzhno-Kurilsk Mendeleyevo Airport). Gidrostroy, the Kurils' biggest business group with interests in fishing, construction and real estate, built its second fish processing factory on Iturup island in 2006, introducing a state-of-the-art conveyor system. To deal with a rise in the demand of electricity, the local government is also upgrading a state-run geothermal power plant at Mount Baransky, an active volcano, where steam and hot water can be found. In 2022, a special economic zone was established on the Kuril islands with special tax regimes, exemption from corporate income tax, VAT with reduced customs duties for 20 years. It is an important part of Russian government's plan to develop the Russian far east.
These 35 are known as primordial radionuclides. Well-known examples are uranium and thorium, but also included are naturally occurring long-lived radioisotopes, such as potassium-40. Each of the heavy primordial radionuclides participates in one of the four decay chains.
In this process, the signal, by interacting with the receptor, starts a series of molecular events within the cell leading to the final effect of the signaling process. Typically the final effect consists in the activation of an ion channel (ligand-gated ion channel) or the initiation of a second messenger system cascade that propagates the signal through the cell. Second messenger systems can amplify or modulate a signal, in which activation of a few receptors results in multiple secondary messengers being activated, thereby amplifying the initial signal (the first messenger). The downstream effects of these signaling pathways may include additional enzymatic activities such as proteolytic cleavage, phosphorylation, methylation, and ubiquitinylation. Signaling molecules can be synthesized from various biosynthetic pathways and released through passive or active transports, or even from cell damage. Each cell is programmed to respond to specific extracellular signal molecules, and is the basis of development, tissue repair, immunity, and homeostasis. Errors in signaling interactions may cause diseases such as cancer, autoimmunity, and diabetes.
== Early life == He is the fifth son of Sheikh Zayed bin Sultan Al Nahyan, the founder and first President of the United Arab Emirates. His mother is Sheikha Fatima bint Mubarak Al Ketbi and he has five full-brothers: Mohammed, Hamdan, Tahnoun, Mansour, and Abdullah.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.